ASX-Dividend-Report-Banner
Sponsored

Imugene (ASX: IMU) doses first patient in Phase 1 bile tract cancer trial

July 10, 2024 12:05 PM AEST | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Imugene (ASX: IMU) doses first patient in Phase 1 bile tract cancer trial
Image source: Company website

Highlights

  • The first patient in the Phase 1 bile tract cancer trial has been dosed.
  • The trial is expected to enrol 10 patients with bile tract cancer.
  • The sixth high dose cohort of both arms of the Phase 1 MAST monotherapy dose escalation trial is open and enrolling.

Imugene Limited (ASX: IMU) has dosed the first patient in its Phase 1 bile tract cancer (cholangiocarcinoma) trial. This trial marks the expansion of the MAST (Metastatic Advanced Solid Tumours) Phase 1 study, following promising responses in gastrointestinal cancers, particularly bile tract cancer, using VAXINIA, an oncolytic virus CF33.

The trial is being conducted at St. Vincent’s Hospital and aims to enrol 10 patients with bile tract cancer.

Triggered by the update, IMU shares jumped 7.8% to trade at AU$0.055 apiece at the time of writing on 10 July 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.